51 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
or indirect access to any of the Disclosing Party’s Confidential Information.
The Receiving Party may disclose Confidential Information to the extent
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
and access. Even if the patient populations meet Tenet’s size estimates and growth forecasts, its business may not grow at similar rates, or at all … condition and prospects. Any products that Tenet may develop may compete with other product candidates and products for access to manufacturing
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
written notice, Buyer shall, and shall cause its Affiliates and sublicensees to, up to [***] per Calendar Year, provide the Accounting Firm with access … such agreement contains provisions that would allow Buyer or its Affiliates and sublicensees to obtain and provide to the Accounting Firm such access
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
receiving CD19-directed CAR-T therapy. Tenet believes that an anti-CD19 antibody approach has the potential to access and deplete tissue-level B-cell niches … on whether or not a study should move forward at designated check points based on access to certain data from the study and may halt the clinical trial
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
webcast will start at 9:00 a.m., Eastern time on Wednesday, June 26, 2024. Online access to the audio webcast will open 15 minutes prior to the start … not be able to access sufficient capital on acceptable terms, if at all, and, as a result, it may be required to delay, scale back or discontinue
PREM14A
e1pz8nhuuo2w
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
pc866l7i
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
x1ense t6y
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.3
pv9hr v5c3i
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.1
jgr4 blvi
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.2
bmum3xfn94uayozrg u5
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
DEFA14A
a1n4k3qxv
6 Apr 23
Additional proxy soliciting materials
4:10pm